Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07584720 · ClinicalTrials.gov registry record · Phase 1
Study of Midomafetamine in Healthy Adults
A Phase 1 study, sponsored by Resilient Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT07584720: Active Phase 1 study, sponsored by Resilient Pharmaceuticals.
NCT07584720 is a Phase 1 study that is active but no longer recruiting, run by Resilient Pharmaceuticals. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07584720, a Phase 1 study, is active but no longer recruiting, sponsored by Resilient Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This Phase 1 study is designed to evaluate the safety and tolerability of midomafetamine in healthy adult participants. The study will also assess how the drug is processed in the body and characterize its effects following administration at two dose levels, including evaluation of cardiac safety using electrocardiographic assessments. This is a single-center, open-label study in which participants will be enrolled into one of two cohorts receiving either a therapeutic dose or a supratherapeutic dose of midomafetamine. Participants will receive study drug in a split dose administration (an initial dose followed by an additional dose 1.5 hours later) and will undergo clinical assessments, laboratory testing, electrocardiographic monitoring, and monitoring for adverse events. Information collected from this study will be used to support the ongoing clinical development of midomafetamine.
Interventions
- DRUG Midomafetamine HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-04-23 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07584720
The ClinicalTrials.gov registry entry for NCT07584720 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Resilient Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Midomafetamine HCl is the first listed.
NCT07584720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07584720 about?
NCT07584720 is a clinical study titled "Study of Midomafetamine in Healthy Adults". This Phase 1 study is designed to evaluate the safety and tolerability of midomafetamine in healthy adult participants. The study will also assess how the drug is processed in the body and characterize its effects following administration at two dose levels, including evaluation of cardiac safety us...
What is the current status of trial NCT07584720?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-04-23. Estimated completion is 2027-02-28.
What interventions are being tested in trial NCT07584720?
The interventions under investigation include: Midomafetamine HCl (DRUG).
Who is sponsoring clinical trial NCT07584720?
This trial is sponsored by Resilient Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.